ADAMTSL2 and metabolic dysfunction-associated steatohepatitis: MCP-1 demonstrated a low level of diagnostic accuracy for detecting significant and advanced fibrosis among NASH patients [20], while NFPP and ADAMTSL2 showed promising results in the detection of advanced fibrosis among NAFLD patients (AUROC of 0.830) [30].